GENFIT Financial Update: Significant Progress
GENFIT, a biopharmaceutical company dedicated to enhance the lives of patients with severe liver diseases, has reported impressive financial results as of September 30, 2025. The company's cash position shows a strong foundation upon which they can advance their innovative research.
Strong Cash Reserves
As of September 30, 2025, GENFIT reported cash and cash equivalents totaling €119.0 million. This figure represents a notable increase from €107.5 million reported on June 30, 2025, and €81.8 million from December 31, 2024. These substantial cash reserves are expected to support the company’s operations and developmental activities well into 2028.
Funding Future Initiatives
The robust cash position allows GENFIT to effectively manage its operating expenses and accelerate the development of its pipeline. The company has plans to focus on treatments for Acute on-Chronic Liver Failure (ACLF) and to ensure its overall corporate health. The strategy is predicated on the anticipated commercial milestone revenues and leveraging a Royalty Financing agreement.
Revenue Details
For the first nine months of 2025, GENFIT reported revenues of €39.2 million, a decrease from €59.7 million for the same period in 2024. This revenue mainly stems from a significant milestone payment related to Iqirvo (elafibranor), which received pricing and reimbursement approvals in major European markets.
Role of Licensing Agreements
The company's revenue is bolstered by its licensing agreement with Ipsen, which has generated €12.6 million in royalties from global Iqirvo sales. The milestone payment of €26.5 million reflects the successful navigation of essential regulatory hurdles.
Pioneering Pipeline Developments
GENFIT continues to push the boundaries in liver disease research, particularly in its pipeline addressing ACLF. The Company is geared toward innovative treatments aimed at improving patient outcomes.
ACLF Pipeline Progress
Current trials are focusing on pivotal programs such as G1090N, SRT-015, and VS-02-HE. With clinical milestones approaching, the company anticipates valuable data outputs from their ongoing studies, particularly concerning the efficacy and safety of these new therapeutic options.
Commitment to Innovation
GENFIT's long-term vision is rooted in its pioneering spirit in liver disease treatment. Their comprehensive portfolio encompasses various conditions, including biliary cholangitis and cholangiocarcinoma. Their commitment to R&D ensures that they remain at the forefront of discovering life-saving therapies.
Collaboration Insights
Strategic collaborations are crucial for GENFIT, as evidenced by their partnership with Ipsen. These collaborations not only enhance financial stability but also expand the reach of GENFIT’s innovative products in viables markets.
About GENFIT
With headquarters in Lille, France, and additional offices in Paris, Zurich, and Cambridge, MA, GENFIT stands as a significant player in the biopharmaceutical landscape. Their dedication to addressing unmet medical needs in liver diseases highlights their importance in the healthcare sector.
Contact Information
For more information, investors and media can reach out to GENFIT:
Investors: Tel: +33 3 2016 4000 | Email: investors@genfit.com
Media: Stephanie Boyer | Tel: +33 3 2016 4000 | Email: stephanie.boyer@genfit.com
Frequently Asked Questions
What is GENFIT focused on?
GENFIT aims to improve lives through innovative therapies targeting rare and life-threatening liver diseases.
How much cash does GENFIT currently have?
As of September 30, 2025, GENFIT reported cash and cash equivalents of €119.0 million.
What drove GENFIT's revenues in 2025?
The company's revenues were primarily driven by milestone payments and royalties from the licensing agreement with Ipsen regarding Iqirvo.
What are GENFIT’s upcoming clinical trials focused on?
GENFIT is focusing on ACLF treatments, with ongoing trials for compounds such as G1090N and SRT-015.
Who can be contacted for more information about GENFIT?
Interested parties can contact GENFIT through their investor relations or media relations teams as listed above.
